Bendell, J. C., Reddy, V., Tavakkoli, F., Leow, C. C., Li, X., Kumar, R., & Strickler, J. H. (2016). A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors. In Journal of Clinical Oncology (Vol. 34, pp. TPS3096–TPS3096). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.tps3096

Bendell, Johanna C., Vijay Reddy, Fatemeh Tavakkoli, Ching Ching Leow, Xia Li, Rakesh Kumar, and John H. Strickler. “A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.” In Journal of Clinical Oncology, 34:TPS3096–TPS3096. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps3096.

Bendell JC, Reddy V, Tavakkoli F, Leow CC, Li X, Kumar R, et al. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS3096–TPS3096.

Bendell, Johanna C., et al. “A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. TPS3096–TPS3096. Crossref, doi:10.1200/jco.2016.34.15_suppl.tps3096.

Bendell JC, Reddy V, Tavakkoli F, Leow CC, Li X, Kumar R, Strickler JH. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS3096–TPS3096.